Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records
Results unveil a large proportion of patients who do not benefit from state-of-the-art subsequent LOT, and suggest diminishing effectiveness with each subsequent LOT.
Authors
- Armando Orlandi (ORCID: https://orcid.org/0000-0001-5253-4678)
- Catherine Hogg
- Mahéva Vallet (ORCID: https://orcid.org/0000-0001-7007-0782)
- Markus Lucerna
- Emilio Bria (ORCID: https://orcid.org/0000-0002-2333-704X)
- Paul Henri Cottu (ORCID: https://orcid.org/0000-0001-6434-3932)
- Peter S Hall (ORCID: https://orcid.org/0000-0001-6015-7841)
- Achim Wöckel (ORCID: https://orcid.org/0000-0002-6767-9666)
- Shivani Aggarwal
- Joana Moreira
- Amanda Logue
- Nicolas Niklas
- Nuria Ribelles (ORCID: https://orcid.org/0000-0003-3194-7398)
- Gráinne H. Long (ORCID: https://orcid.org/0000-0001-5080-9885)
- Simon M. Collin (ORCID: https://orcid.org/0000-0002-1239-1681)
- Christian W. Scholz (ORCID: https://orcid.org/0000-0001-6260-4086)
- Sue Cheeseman (ORCID: https://orcid.org/0000-0002-9671-4715)
Institutions
- NHS Lothian (GB)
- Daiichi Sankyo (Germany) (DE)
- Université Paris Cité (FR)
- Landmark College (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Western General Hospital (GB)
- Agostino Gemelli University Polyclinic (IT)
- IQVIA (United Kingdom) (GB)
- Vivantes Klinikum (DE)
- AstraZeneca (France) (FR)
- Universitätsklinikum Würzburg (DE)
- AstraZeneca (Poland) (PL)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Institut Curie (FR)
- University of Edinburgh (GB)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1007/s10549-024-07506-4
- Citations
- 5
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- AstraZeneca
- Daiichi Sankyo Europe